有孕前糖尿病的女性的避孕措施使用情况。

Contraception utilization in women with pregestational diabetes.

机构信息

Institute for Health and Equity (IHE), Medical College of Wisconsin, Milwaukee, WI, USA.

Center for Advancing Population Science (CAPS), Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Eur J Contracept Reprod Health Care. 2022 Aug;27(4):317-321. doi: 10.1080/13625187.2022.2074392. Epub 2022 Jun 6.

DOI:10.1080/13625187.2022.2074392

PMID:35946609

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9759819/

Abstract

OBJECTIVE

To compare contraception use between women with and without pregestational diabetes.

METHODS

Cross-sectional data on women aged 18-44 years from 2011 to 2017 National Survey of Family Growth (NSFG) was analysed. Maternal diabetes was defined as the presence of pre-gestational type 1 or type 2 diabetes. Bivariate and multiple logistic regression analyses were run to evaluate the association between the use of contraception and by contraception type: permanent, long-acting reversible contraception (LARC), other hormonal method, other non-hormonal method, and none, and maternal diabetes status, controlling for relevant covariates.

RESULTS

Among the total study sample of 28,454, 1344 (4.7%) had pregestational diabetes. Unadjusted analysis showed women with a history of pregestational diabetes were more likely to use permanent contraception following pregnancy (58.0% vs. 38.7%, < 0.001) or no contraception (27.2% vs. 24.5%, < 0.001), but less likely to use LARC (3.4% vs. 11.7%, < 0.001), other hormonal contraception (4.1% vs. 8.9%, < 0.001), or other non-hormonal contraception (7.2% vs. 16.4%, < 0.001). In adjusted analyses, permanent (aOR 1.62, 95% CI 0.72-2.26) remained significant, however the differences were no longer statistically significant: LARC (aOR 0.34, 95% CI 0.12-1.00); other hormonal (aOR 0.61, 95% CI 0.27-1.35); other non-hormonal (aOR 0.59, 95% CI 0.25-1.43); and None (aOR 1.11, 95% CI 0.65-1.89).

CONCLUSION

In this analysis, we found that women with pregestational diabetes were more likely to use permanent contraception methods compared to women without pregestational diabetes; however over a quarter of women with pregestational diabetes did not use contraception between pregnancies.

摘要

目的

比较患有和不患有孕前糖尿病的女性的避孕方法使用情况。

方法

对 2011 年至 2017 年全国家庭增长调查（NSFG）中年龄在 18-44 岁的女性进行横断面数据分析。母体糖尿病定义为患有孕前 1 型或 2 型糖尿病。使用二变量和多变量逻辑回归分析评估避孕方法的使用情况与避孕类型之间的关联：永久性、长效可逆避孕（LARC）、其他激素方法、其他非激素方法和无避孕方法，并控制相关协变量。

结果

在总计 28454 名研究对象中，有 1344 名（4.7%）患有孕前糖尿病。未调整分析显示，有孕前糖尿病史的女性在妊娠后更有可能使用永久性避孕方法（58.0% vs. 38.7%，<0.001）或不使用任何避孕方法（27.2% vs. 24.5%，<0.001），但不太可能使用 LARC（3.4% vs. 11.7%，<0.001）、其他激素避孕方法（4.1% vs. 8.9%，<0.001）或其他非激素避孕方法（7.2% vs. 16.4%，<0.001）。在调整分析中，永久性（aOR 1.62，95%CI 0.72-2.26）仍然显著，但差异不再具有统计学意义：LARC（aOR 0.34，95%CI 0.12-1.00）；其他激素（aOR 0.61，95%CI 0.27-1.35）；其他非激素（aOR 0.59，95%CI 0.25-1.43）；以及无避孕方法（aOR 1.11，95%CI 0.65-1.89）。